



		AfeI						XhoI					BstBI					EcoRI	
2790	ATC	GCT	AGC	GCT	ACC	GGA	CTC	AGA	TCT	CGA	GCT	CAA	GCT	TCG	AAT	TCT			
2838	GCA	GTC	GAC	GGT	ACC	GCG	GGC	CCG	GGA	TCC	CGC	GAC	TCT	AGA	GGA	GTG			

#### pLVX-PTunerC Vector Map and Multiple Cloning Site (MCS).

#### Description

pLVX-PTunerC is a bicistronic, HIV-1-based, lentiviral expression vector that allows you to precisely regulate the amount of your protein of interest in virtually any mammalian cell type, including primary cells. The vector encodes a 12 kDa, FKBP-based destabilization domain (DD-C) that has been optimized for use as a C-terminal tag (1). This domain, located just downstream of the multiple cloning site (MCS), causes the rapid degradation of any protein to which it is fused. Degradation of the DD-C-tagged protein can be prevented by the addition of Shield1 stabilizing ligand to the medium. Shield1 is a membrane permeant molecule that binds to the DD-C tag, 'shielding' the fusion protein from proteasomal degradation, causing the rapid accumulation of the C-terminally tagged protein of interest.

pLVX-PTunerC contains all of the viral processing elements necessary for the production of replication-incompetent lentivirus, as well as elements to improve viral titer, transgene expression, and overall vector function. The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) promotes RNA processing events and enhances nuclear export of viral and transgene RNA (2), leading to increased viral titers from packaging cells and enhanced expression of your gene of interest in target cells. In addition, the vector includes a Rev-response element (RRE), which further increases viral titers by enhancing the transport of unspliced viral RNA out of the nucleus (3). Finally, pLVX-PTunerC also contains a central polypurine tract/central termination sequence element (cPPT/CTS). During target cell infection, this element creates a central DNA flap that increases nuclear import of the viral genome, resulting in improved vector integration and more efficient transduction (4).

(PR113808; published 17 January 2011)



**Clontech**

United States/Canada  
800.662.2566

Asia Pacific  
+1.650.919.7300

Europe  
+33.(0)1.3904.6880

Japan  
+81.(0)77.543.6116

Clontech Laboratories, Inc.  
A Takara Bio Company  
1290 Terra Bella Ave.  
Mountain View, CA 94043  
Technical Support (US)  
E-mail: tech@clontech.com  
www.clontech.com

In addition to lentiviral elements, pLVX-PTunerC contains a puromycin resistance gene (Puro<sup>r</sup>) under the control of the murine phosphoglycerate kinase promoter ( $P_{PGK}$ ). Turnover of the Puro<sup>r</sup> gene product is unaffected by the DD-C tag, so puromycin resistance can be used as an indicator of transduction efficiency and a marker for selection. The vector also contains a pUC origin of replication and an *E. coli* ampicillin resistance gene (Amp<sup>r</sup>) for propagation and selection in bacteria.

### Use

pLVX-PTunerC is available in the Lenti-X™ ProteoTuner™ Shield System C (Cat. No. 631074). The vector is designed to constitutively coexpress a C-terminally DD-C-tagged protein of interest and puromycin resistance when transduced into mammalian cells. To create your DD-C-tagged protein of interest, your gene of interest must contain no in-frame stop codons, and must be cloned into the MCS in the same reading frame as the DD-C tag sequence. Before it can be transduced into target cells, the vector must be cotransfected into 293T cells with our Lenti-X™ HT Packaging System (Cat. Nos. 632160 and 632161) and packaged into viral particles. This packaging system allows the safe production of high titer, infectious, replication-incompetent, VSV-G pseudotyped lentiviral particles that can infect a wide range of cell types, including non-dividing and primary cells (5).

When cells expressing a DD-C-tagged protein of interest are grown in medium containing Shield1, the ligand binds to the DD-C tag and protects the fusion protein from degradation. As a result, the protein quickly accumulates inside the cells in amounts that are directly proportional to the concentration of Shield1 in the medium. If the cells are subsequently grown in medium lacking Shield1, the DD-C tag is no longer stabilized and the fusion protein is rapidly degraded. Because the effects of Shield1 are concentration-dependent and reversible, it is possible to fine-tune the amount of fusion protein present in the cells simply by adjusting the concentration of the ligand in the medium (6).

### Location of Features

- 5' LTR: 1–635
- PBS (primer binding site): 636–653
- Ψ (packaging signal): 685–822
- RRE (Rev-response element): 1303–1536
- cPPT/CTS (central polypurine tract/central termination sequence): 2031–2151
- $P_{CMVIE}$  (human cytomegalovirus immediate early promoter): 2185–2787
- MCS (multiple cloning site): 2815–2867
- DD-C (destabilization domain, optimized for use as a C-terminal tag): 2880–3200
- $P_{PGK}$  (phosphoglycerate kinase promoter): 3211–3719
- Puro<sup>r</sup> (puromycin resistance gene; puromycin N-acetyltransferase): 3740–4339
- WPRE (woodchuck posttranscriptional regulatory element): 4353–4944
- 3' LTR: 5148–5784
- pUC origin of replication: 6254–6924 (complementary)
- Amp<sup>r</sup> (ampicillin resistance gene; β-lactamase): 7069–8065 (complementary)

### Selection of Stable Transfectants

- Selectable marker: plasmid confers resistance to puromycin.

### Propagation in *E. coli*

- Suitable host strains: Stellar™ Competent Cells.
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) in *E. coli* hosts.
- *E. coli* replication origin: pUC

### References

1. Chu, B. W. *et al.* (2008) *Bioorg. Med. Chem. Lett.* **18**(22):5941–5944.
2. Zufferey, R. *et al.* (1999) *J. Virol.* **73**(4):2886–2892.
3. Cochrane, A. W. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**(3):1198–1202.
4. Zennou, V. *et al.* (2000) *Cell* **101**(2):173–185.
5. Wu, X. *et al.* (2000) *Mol. Ther.* **2**(1):47–55.
6. Banaszynski, L. *et al.* (2006) *Cell* **126**(5):995–1004.

**Notes:**

The vector sequence was compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

The viral supernatants produced by this lentiviral vector could contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant lentivirus. Appropriate NIH, regional, and institutional guidelines apply.

**Notice to Purchaser**

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Clontech has a license to sell products containing the WPRE, under the terms described below. Any use of WPRE outside of Clontech's Product or the Product's intended use, requires a license as detailed below. Before using the Product containing WPRE, please read the following license agreement. If you do not agree to be bound by its terms, contact Clontech within 10 days for authorization to return the unused Product containing WPRE and to receive a full credit. Patents: The WPRE technology is covered by one or more of the following US patents and corresponding patent claims outside the US: 6,136,597 ; 6,284,469 ; 6,312,912 ; 6,287,814 , issued to The Salk Institute for Biological Studies; Individual License Agreement: Clontech grants you a non-exclusive license to use the enclosed Product containing WPRE in its entirety for its intended use. The Product containing WPRE is being transferred to you in furtherance of, and reliance on, such license. Any use of WPRE outside of Clontech's Product or the Product's intended use, requires a license from the Salk Institute for Biological Studies. Termination of License: This license agreement is effective until terminated. You may terminate it at any time by destroying all Products containing WPRE in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Products containing WPRE in your control, and so notify Clontech in writing. This License shall be governed in its interpretation and enforcement by the laws of the State of California. Contact for WPRE Licensing: The Salk Institute for Biological Studies , 10010 North Torrey Pines Road, La Jolla, CA 92037, Attn.: Office of Technology Management , Phone: 858.453.4100 ext. 1275 , Fax: 858.546.8093.

This product and its use are the subject of U.S. Pat. No. 6,682,907. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Clontech is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 ([www.pasteur.fr](http://www.pasteur.fr)).

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2011 Clontech Laboratories, Inc.